Comparative Pharmacology
Head-to-head clinical analysis: JANUMET versus SITAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUMET versus SITAGLIPTIN.
JANUMET vs SITAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janumet is a combination of sitagliptin, a DPP-4 inhibitor, and metformin, a biguanide. Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases active incretin (GLP-1 and GIP) levels by preventing their degradation, thereby enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
Initial dose: 50 mg sitagliptin/500 mg metformin hydrochloride twice daily orally with meals. Dose may be increased up to 50 mg sitagliptin/1000 mg metformin twice daily based on glycemic response and tolerability.
100 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateSitagliptin + Gatifloxacin
"Sitagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSitagliptin + Rosoxacin
"Sitagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSitagliptin + Levofloxacin
"Sitagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSitagliptin + Trovafloxacin
"Sitagliptin may increase the hypoglycemic activities of Trovafloxacin."
Sitagliptin: 12.4 hours (terminal). Clinical context: supports once-daily dosing, but half-life increases in renal impairment. Metformin: 6.2 hours (terminal). Shorter half-life requires multiple daily dosing; prolonged in renal impairment.
12.4 hours; supports once-daily dosing with effect ≥24 h due to sustained DPP-4 inhibition.
Sitagliptin: 87% renal (unchanged), 13% fecal (metabolites). Metformin: 90-100% renal (unchanged), <5% fecal.
Renal: ~87% unchanged in urine (active tubular secretion); fecal: <13% (metabolites).
Category C
Category A/B
DPP-4 Inhibitor/Biguanide Combination
DPP-4 Inhibitor